Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Nasopharyngeal Carcinoma 11Squamous Cell Carcinoma of Head and Neck 6Head and Neck Neoplasms 6Thyroid Neoplasms 4Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Thyroid Diseases 1Sarcoma 1Salivary Gland Neoplasms 1Radioactive Iodine-refractory Differentiated Thyroid Cancer 1Neoplasms, Connective and Soft Tissue 1Neoplasms 1Mouth Neoplasms 1Locally Advanced Thyroid Gland Carcinoma 1Epstein-Barr Virus Infections 1Differentiated Thyroid Cancer 1

Interventions

Thyrotropin Alfa 4donafenib 2Injections 2vandetanib 1surufatinib 1pembrolizumab 1lenvatinib 1apatinib 1anlotinib 1Sorafenib 1Iodine-131 1Everolimus 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Differentiated Thyroid Cancer × apatinib × Head & Neck × Clear all
NCT03048877 2023-04-12

Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer

Peking Union Medical College Hospital

Phase 3 Unknown
118 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡